Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Commissioner’s Office To Be Re-aligned Further Under Booz Allen Plan

Executive Summary

FDA's Office of the Commissioner will be re-aligned further by the end of fiscal year 2003 with the assistance of Booz Allen Hamilton consultants

You may also be interested in...



FDA Strategic Plan: Outsourcing Reviews For One-Third Of FTEs By 2006

FDA expects to complete reviews of competitive outsourcing opportunities for certain accounting and clerical services by the end of fiscal year 2004

FDA Shared Services Chief Expected To Be Selected By July

FDA is targeting early July for selection of a candidate to oversee the agency's new Office of Shared Services, which is slated to begin operations by Oct. 1

CDER Organizational Development Team To Be Headed By EPA’s Wright

CDER's Organizational Development & Strategic Planning Team will be headed by Kenneth Wright, who led several organizational changes during his 25-year tenure at the Environmental Protection Agency

Related Content

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel